Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: The Toronto consensus

Gastroenterology

Volumn 148, Issue 5, 2015, Pages 1035-1058.e3

  Bressler, Brian ^a   Marshall, John K ^b   Bernstein, Charles N ^c   Bitton, Alain ^d   Jones, Jennifer ^e   Leontiadis, Grigorios I ^b   Panaccione, Remo ^f   Steinhart, A Hillary ^g   Tse, Francis ^b   Feagan, Brian ^h  

^a ST PAUL S HOSPITAL   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF MANITOBA   (Canada)

^d MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^e UNIVERSITY OF SASKATCHEWAN   (Canada)

^f UNIVERSITY OF CALGARY   (Canada)

^g UNIVERSITY OF TORONTO   (Canada)

^h ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

5 Aminosalicylate; Anti Tumor Necrosis Factor; Corticosteroid; Probiotics; Thiopurine; Ulcerative Colitis; Vedolizumab

Indexed keywords

BUDESONIDE; CORTICOSTEROID; ENEMA; IMMUNOSUPPRESSIVE AGENT; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; TUMOR NECROSIS FACTOR INHIBITOR; VEDOLIZUMAB; ANTIINFLAMMATORY AGENT; GASTROINTESTINAL AGENT;

AMBULATORY CARE; ARTICLE; CATARACT; CLINICAL EVALUATION; CONSENSUS; CONTROLLED CLINICAL TRIAL (TOPIC); CORTICOSTEROID THERAPY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG MONITORING; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; MAINTENANCE THERAPY; META ANALYSIS (TOPIC); MONOTHERAPY; MYOPATHY; OSTEOPOROSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROCTITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REMISSION; SYSTEMATIC REVIEW; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; COLITIS, ULCERATIVE; CONSENSUS DEVELOPMENT; DRUG COMBINATION; EVIDENCE BASED MEDICINE; GASTROENTEROLOGY; SEVERITY OF ILLNESS INDEX; STANDARDS; TREATMENT OUTCOME;

AMBULATORY CARE; ANTI-INFLAMMATORY AGENTS; COLITIS, ULCERATIVE; CONSENSUS; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; GASTROENTEROLOGY; GASTROINTESTINAL AGENTS; HUMANS; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84928623552     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2015.03.001     Document Type: Article

References (165)

1. A. Rocchi, E.I. Benchimol, and C.N. Bernstein Inflammatory bowel disease: a Canadian burden of illness review Can J Gastroenterol 26 2012 811 817
2. N.A. Molodecky, I.S. Soon, and D.M. Rabi Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review Gastroenterology 142 2012 46 54 e42 quiz e30
3. M.D. Kappelman, K.R. Moore, and J.K. Allen Recent trends in the prevalence of Crohn's disease and ulcerative colitis in a commercially insured US population Dig Dis Sci 58 2013 519 525
4. G.C. Nguyen, A. Tuskey, and T. Dassopoulos Rising hospitalization rates for inflammatory bowel disease in the United States between 1998 and 2004 Inflamm Bowel Dis 13 2007 1529 1535
5. M.D. Kappelman, S.L. Rifas-Shiman, and C.Q. Porter Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults Gastroenterology 135 2008 1907 1913
6. C. Render, and S. Daniels 2011 Canadian Association of Gastroenterology educational needs assessment report Can J Gastroenterol 25 2011 244 246
7. A. Dignass, J.O. Lindsay, and A. Sturm Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management J Crohns Colitis 6 2012 991 1030
8. A. Dignass, R. Eliakim, and F. Magro Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis J Crohns Colitis 6 2012 965 990
9. A. Bitton, D. Buie, and R. Enns Treatment of hospitalized adult patients with severe ulcerative colitis: Toronto consensus statements Am J Gastroenterol 107 2012 179 194 author reply 195
10. G.H. Guyatt, A.D. Oxman, and G.E. Vist GRADE: an emerging consensus on rating quality of evidence and strength of recommendations BMJ 336 2008 924 926
11. N. Dalkey An experimental study of group opinion: the Delphi method Futures 1 1969 408 426
12. D.J. Cook, N.L. Greengold, and A.G. Ellrodt The relation between systematic reviews and practice guidelines Ann Intern Med 127 1997 210 216
13. G.H. Guyatt, A.D. Oxman, and R. Kunz Going from evidence to recommendations BMJ 336 2008 1049 1051
14. J. Satsangi, M.S. Silverberg, and S. Vermeire The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications Gut 55 2006 749 753
15. K.W. Schroeder, W.J. Tremaine, and D.M. Ilstrup Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study N Engl J Med 317 1987 1625 1629
16. S. Ardizzone, A. Cassinotti, and P. Duca Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis Clin Gastroenterol Hepatol 9 2011 483 489 e3
17. D. Laharie, J. Filippi, and X. Roblin Impact of mucosal healing on long-term outcomes in ulcerative colitis treated with infliximab: a multicenter experience Aliment Pharmacol Ther 37 2013 998 1004
18. J.F. Colombel, P. Rutgeerts, and W. Reinisch Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis Gastroenterology 141 2011 1194 1201
19. G. D'Haens, W.J. Sandborn, and B.G. Feagan A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis Gastroenterology 132 2007 763 786
20. A.M. Schoepfer, C. Beglinger, and A. Straumann Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes Inflamm Bowel Dis 19 2013 332 341
21. I.C. Solberg, I. Lygren, and J. Jahnsen Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study) Scand J Gastroenterol 44 2009 431 440
22. A.N. Ananthakrishnan, M. Issa, and D.B. Beaulieu History of medical hospitalization predicts future need for colectomy in patients with ulcerative colitis Inflamm Bowel Dis 15 2009 176 181
23. E. Langholz, P. Munkholm, and M. Davidsen Changes in extent of ulcerative colitis: a study on the course and prognostic factors Scand J Gastroenterol 31 1996 260 266
24. M. Henriksen, J. Jahnsen, and I. Lygren C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study Gut 57 2008 1518 1523
25. D. Turner, C.M. Walsh, and A.H. Steinhart Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression Clin Gastroenterol Hepatol 5 2007 103 110
26. O. Hoie, F. Wolters, and L. Riis Ulcerative colitis: patient characteristics may predict 10-yr disease recurrence in a European-wide population-based cohort Am J Gastroenterol 102 2007 1692 1701
27. S. Ardizzone, M. Petrillo, and P. Molteni Coated oral 5-aminosalicylic acid (Claversal) is equivalent to sulfasalazine for remission maintenance in ulcerative colitis. A double-blind study J Clin Gastroenterol 21 1995 287 289
28. P. Fockens, C.J. Mulder, and G.N. Tytgat Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Dutch Pentasa Study Group Eur J Gastroenterol Hepatol 7 1995 1025 1030
29. W.A. Faubion Jr., E.V. Loftus Jr., and W.S. Harmsen The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study Gastroenterology 121 2001 255 260
30. J.K. Marshall, M. Thabane, and A.H. Steinhart Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis Cochrane Database Syst Rev 2010 CD004115
31. A.C. Ford, K.J. Khan, and J.P. Achkar Efficacy of oral vs. topical, or combined oral and topical 5-aminosalicylates, in ulcerative colitis: systematic review and meta-analysis Am J Gastroenterol 107 2012 167 176 author reply 177
32. J.K. Marshall, and E.J. Irvine Rectal aminosalicylate therapy for distal ulcerative colitis: a meta-analysis Aliment Pharmacol Ther 9 1995 293 300
33. J.K. Marshall, and E.J. Irvine Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis Am J Gastroenterol 95 2000 1628 1636
34. R. Bergman, and M. Parkes Systematic review: the use of mesalazine in inflammatory bowel disease Aliment Pharmacol Ther 23 2006 841 855
35. R.D. Cohen, D.M. Woseth, and R.A. Thisted A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis Am J Gastroenterol 95 2000 1263 1276
36. F. Manguso, and A. Balzano Meta-analysis: the efficacy of rectal beclomethasone dipropionate vs. 5-aminosalicylic acid in mild to moderate distal ulcerative colitis Aliment Pharmacol Ther 26 2007 21 29
37. P. Gionchetti, F. Rizzello, and A. Venturi Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis Dis Colon Rectum 41 1998 93 97
38. M. Watanabe, H. Nishino, and Y. Sameshima Randomised clinical trial: evaluation of the efficacy of mesalazine (mesalamine) suppositories in patients with ulcerative colitis and active rectal inflammation - a placebo-controlled study Aliment Pharmacol Ther 38 2013 264 273
39. A. Ekbom, C. Helmick, and M. Zack Ulcerative colitis and colorectal cancer. A population-based study N Engl J Med 323 1990 1228 1233
40. A.A. van Bodegraven, R.O. Boer, and J. Lourens Distribution of mesalazine enemas in active and quiescent ulcerative colitis Aliment Pharmacol Ther 10 1996 327 332
41. J. Brown, S. Haines, and I.R. Wilding Colonic spread of three rectally administered mesalazine (Pentasa) dosage forms in healthy volunteers as assessed by gamma scintigraphy Aliment Pharmacol Ther 11 1997 685 691
42. R. Eliakim, Z. Tulassay, and L. Kupcinskas Clinical trial: randomized-controlled clinical study comparing the efficacy and safety of a low-volume vs. a high-volume mesalazine foam in active distal ulcerative colitis Aliment Pharmacol Ther 26 2007 1237 1249
43. B.G. Feagan, and J.K. Macdonald Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis Cochrane Database Syst Rev 10 2012 CD000543
44. A.C. Ford, J.P. Achkar, and K.J. Khan Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis Am J Gastroenterol 106 2011 601 616
45. W.J. Sandborn, J. Regula, and B.G. Feagan Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis Gastroenterology 137 2009 1934 1943 e1-3
46. S.B. Hanauer, W.J. Sandborn, and C. Dallaire Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial Can J Gastroenterol 21 2007 827 834
47. S.B. Hanauer, W.J. Sandborn, and A. Kornbluth Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial Am J Gastroenterol 100 2005 2478 2485
48. E.V. Loftus Jr., S.V. Kane, and D. Bjorkman Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis Aliment Pharmacol Ther 19 2004 179 189
49. J.P. Gisbert, Y. Gonzalez-Lama, and J. Mate 5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review Inflamm Bowel Dis 13 2007 629 638
50. R. Pruitt, J. Hanson, and M. Safdi Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis Am J Gastroenterol 97 2002 3078 3086
51. D.S. Levine, D.S. Riff, and R. Pruitt A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis Am J Gastroenterol 97 2002 1398 1407
52. A. Cortot, D. Maetz, and E. Degoutte Mesalamine foam enema versus mesalamine liquid enema in active left-sided ulcerative colitis Am J Gastroenterol 103 2008 3106 3114
53. P.G. Farup, O. Hovde, and F.A. Halvorsen Mesalazine suppositories versus hydrocortisone foam in patients with distal ulcerative colitis. A comparison of the efficacy and practicality of two topical treatment regimens Scand J Gastroenterol 30 1995 164 170
54. F. Hartmann, and J. Stein Clinical trial: controlled, open, randomized multicentre study comparing the effects of treatment on quality of life, safety and efficacy of budesonide or mesalazine enemas in active left-sided ulcerative colitis Aliment Pharmacol Ther 32 2010 368 376
55. M. Lemann, A. Galian, and P. Rutgeerts Comparison of budesonide and 5-aminosalicylic acid enemas in active distal ulcerative colitis Aliment Pharmacol Ther 9 1995 557 562
56. M. Safdi, M. DeMicco, and C. Sninsky A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis Am J Gastroenterol 92 1997 1867 1871
57. M.A. Kamm, G.R. Lichtenstein, and W.J. Sandborn Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis Inflamm Bowel Dis 15 2009 1 8
58. A.C. Ford, K.J. Khan, and W.J. Sandborn Efficacy of topical 5-aminosalicylates in preventing relapse of quiescent ulcerative colitis: a meta-analysis Clin Gastroenterol Hepatol 10 2012 513 519
59. J.K. Marshall, M. Thabane, and A.H. Steinhart Rectal 5-aminosalicylic acid for maintenance of remission in ulcerative colitis Cochrane Database Syst Rev 11 2012 CD004118
60. B.G. Feagan, and J.K. Macdonald Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis Cochrane Database Syst Rev 10 2012 CD000544
61. P. Miner, S. Hanauer, and M. Robinson Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group Dig Dis Sci 40 1995 296 304
62. B.G. Feagan, N. Chande, and J.K. MacDonald Are there any differences in the efficacy and safety of different formulations of Oral 5-ASA used for induction and maintenance of remission in ulcerative colitis? evidence from cochrane reviews Inflamm Bowel Dis 19 2013 2031 2040
63. B.G. Feagan, and J.K. MacDonald Once daily oral mesalamine compared to conventional dosing for induction and maintenance of remission in ulcerative colitis: a systematic review and meta-analysis Inflamm Bowel Dis 18 2012 1785 1794
64. B. Flourie, H. Hagege, and G. Tucat Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis Aliment Pharmacol Ther 37 2013 767 775
65. A.C. Ford, K.J. Khan, and W.J. Sandborn Once-daily dosing vs. conventional dosing schedule of mesalamine and relapse of quiescent ulcerative colitis: systematic review and meta-analysis Am J Gastroenterol 106 2011 2070 2077 quiz 2078
66. A.U. Dignass, B. Bokemeyer, and H. Adamek Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis Clin Gastroenterol Hepatol 7 2009 762 769
67. S.V. Kane, R.D. Cohen, and J.E. Aikens Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis Am J Gastroenterol 96 2001 2929 2933
68. S. Kane, D. Huo, and J. Aikens Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis Am J Med 114 2003 39 43
69. P.D. Higgins, D.T. Rubin, and K. Kaulback Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares Aliment Pharmacol Ther 29 2009 247 257
70. S.V. Kane Strategies to improve adherence and outcomes in patients with ulcerative colitis Drugs 68 2008 2601 2609
71. W. Kruis, G. Kiudelis, and I. Racz Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial Gut 58 2009 233 240
72. W.J. Sandborn, J. Korzenik, and B. Lashner Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis Gastroenterology 138 2010 1286 1296 1296 e1-3
73. A.C. Ford, C.N. Bernstein, and K.J. Khan Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis Am J Gastroenterol 106 2011 590 599 quiz 600
74. M. Campieri, S. Adamo, and D. Valpiani Oral beclometasone dipropionate in the treatment of extensive and left-sided active ulcerative colitis: a multicentre randomised study Aliment Pharmacol Ther 17 2003 1471 1480
75. S.P. Travis, S. Danese, and L. Kupcinskas Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study Gut 63 2014 433 441
76. G.R. Lichtenstein, M.T. Abreu, and R. Cohen American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease Gastroenterology 130 2006 940 987
77. A. Dignass, G. Van Assche, and J.O. Lindsay The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management J Crohns Colitis 4 2010 28 62
78. J.K. Marshall, and E.J. Irvine Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis Gut 40 1997 775 781
79. Topical 5-aminosalicylic acid versus prednisolone in ulcerative proctosigmoiditis. A randomized, double-blind multicenter trial. Danish 5-ASA Group Dig Dis Sci 32 1987 598 602
80. F.I. Lee, D.P. Jewell, and V. Mani A randomised trial comparing mesalazine and prednisolone foam enemas in patients with acute distal ulcerative colitis Gut 38 1996 229 233
81. S. Bar-Meir, H.H. Fidder, and M. Faszczyk Budesonide foam vs. hydrocortisone acetate foam in the treatment of active ulcerative proctosigmoiditis Dis Colon Rectum 46 2003 929 936
82. W. Sandborn, B. Bosworth, and S. Zakko Efficacy and safety of budesonide foam for inducing remission in mildly to moderately active ulcerative proctitis or ulcerative proctosigmoiditis (abstr P-149) Inflamm Bowel Dis 19 suppl 1 2013 S83
83. J. Powell-Tuck, R.L. Bown, and T.J. Chambers A controlled trial of alternate day prednisolone as a maintenance treatment for ulcerative colitis in remission Digestion 22 1981 263 270
84. J.E. Lennard-Jones, J.J. Misiewicz, and A.M. Connell Prednisone as maintenance treatment for ulcerative colitis in remission Lancet 1 1965 188 189
85. S.C. Truelove, and L.J. Witts Cortisone and corticotrophin in ulcerative colitis Br Med J 1 1959 387 394
86. I. Bjarnason, A. Macpherson, and C. Mackintosh Reduced bone density in patients with inflammatory bowel disease Gut 40 1997 228 233
87. G.R. Lichtenstein, B.G. Feagan, and R.D. Cohen Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT registry Am J Gastroenterol 107 2012 1409 1422
88. W.J. Sandborn, S. Travis, and L. Moro Once-daily budesonide MMX(R) extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study Gastroenterology 143 2012 1218 1226 e1-2
89. G.R. D'Haens, A. Kovacs, and P. Vergauwe Clinical trial: Preliminary efficacy and safety study of a new Budesonide-MMX(R) 9 mg extended-release tablets in patients with active left-sided ulcerative colitis J Crohns Colitis 4 2010 153 160
90. R. Lofberg, A. Danielsson, and O. Suhr Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis Gastroenterology 110 1996 1713 1718
91. V. Gross, I. Bunganic, and E.A. Belousova 3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: a double-blind, double-dummy, randomised trial J Crohns Colitis 5 2011 129 138
92. M.E. Sherlock, C.H. Seow, and A.H. Steinhart Oral budesonide for induction of remission in ulcerative colitis Cochrane Database Syst Rev 2010 CD007698
93. E.J. Schoon, S. Bollani, and P.R. Mills Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease Clin Gastroenterol Hepatol 3 2005 113 121
94. J.P. Gisbert, P.M. Linares, and A.G. McNicholl Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis Aliment Pharmacol Ther 30 2009 126 137
95. D.P. Jewell, and S.C. Truelove Azathioprine in ulcerative colitis: final report on controlled therapeutic trial Br Med J 4 1974 627 630
96. A. Sood, V. Midha, and N. Sood Role of azathioprine in severe ulcerative colitis: one-year, placebo-controlled, randomized trial Indian J Gastroenterol 19 2000 14 16
97. K.J. Khan, M.C. Dubinsky, and A.C. Ford Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis Am J Gastroenterol 106 2011 630 642
98. S. Ardizzone, G. Maconi, and A. Russo Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis Gut 55 2006 47 53
99. A. Timmer, J.W. McDonald, and D.J. Tsoulis Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis Cochrane Database Syst Rev 9 2012 CD000478
100. A. Sood, V. Kaushal, and V. Midha The beneficial effect of azathioprine on maintenance of remission in severe ulcerative colitis J Gastroenterol 37 2002 270 274
101. A.B. Hawthorne, R.F. Logan, and C.J. Hawkey Randomised controlled trial of azathioprine withdrawal in ulcerative colitis BMJ 305 1992 20 22
102. A. Kornbluth, and D.B. Sachar Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee Am J Gastroenterol 105 2010 501 523 quiz 524
103. M.A. Smith, P.M. Irving, and A.M. Marinaki Review article: malignancy on thiopurine treatment with special reference to inflammatory bowel disease Aliment Pharmacol Ther 32 2010 119 130
104. D.S. Kotlyar, M.T. Osterman, and R.H. Diamond A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease Clin Gastroenterol Hepatol 9 2011 36 41.e1
105. J. Ariyaratnam, and V. Subramanian Association between thiopurine use and nonmelanoma skin cancers in patients with inflammatory bowel disease: a meta-analysis Am J Gastroenterol 109 2014 163 169
106. Health Canada. Imuran (azathioprine) or Purinethol (mercaptopurine) - association with a type of blood cancer - hepatosplenic T-cell lymphoma - for health professionals. Last Update 2014. http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2014/38691a-eng.php. Accessed January 17, 2015.
107. J.K. Marshall, A.R. Otley, and W. Afif Canadian Association of Gastroenterology position statement regarding the use of thiopurines for the treatment of inflammatory bowel disease Can J Gastroenterol Hepatol 28 2014 371 372
108. N. Chande, J.K. MacDonald, and J.W. McDonald Methotrexate for induction of remission in ulcerative colitis Cochrane Database Syst Rev 2007 CD006618
109. W. El-Matary, B. Vandermeer, and A.M. Griffiths Methotrexate for maintenance of remission in ulcerative colitis Cochrane Database Syst Rev 2009 CD007560
110. R. Oren, N. Arber, and S. Odes Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial Gastroenterology 110 1996 1416 1421
111. M. Onuk, S. Kaymakoglu, and K. Demir Low-dose weekly methotrexate therapy in remission maintenance in ulcerative colitis (abstr) Gut 39 1996 A75
112. J. Mate-Jimenez, C. Hermida, and J. Cantero-Perona 6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease Eur J Gastroenterol Hepatol 12 2000 1227 1233
113. L.J. Egan, W.J. Sandborn, and W.J. Tremaine A randomized dose-response and pharmacokinetic study of methotrexate for refractory inflammatory Crohn's disease and ulcerative colitis Aliment Pharmacol Ther 13 1999 1597 1604
114. M. Manosa, V. Garcia, and L. Castro Methotrexate in ulcerative colitis: a Spanish multicentric study on clinical use and efficacy J Crohns Colitis 5 2011 397 401
115. N. Khan, A.M. Abbas, and M. Moehlen Methotrexate in ulcerative colitis: a nationwide retrospective cohort from the Veterans Affairs Health Care System Inflamm Bowel Dis 19 2013 1379 1383
116. A.C. Ford, W.J. Sandborn, and K.J. Khan Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis Am J Gastroenterol 106 2011 644 659 quiz 660
117. M.M. Lawson, A.G. Thomas, and A.K. Akobeng Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis Cochrane Database Syst Rev 2006 CD005112
118. R. Lv, W. Qiao, and Z. Wu Tumor necrosis factor alpha blocking agents as treatment for ulcerative colitis intolerant or refractory to conventional medical therapy: a meta-analysis PLoS One 9 2014 e86692
119. P. Rutgeerts, W.J. Sandborn, and B.G. Feagan Infliximab for induction and maintenance therapy for ulcerative colitis N Engl J Med 353 2005 2462 2476
120. W. Reinisch, W.J. Sandborn, and D.W. Hommes Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial Gut 60 2011 780 787
121. W.J. Sandborn, G. van Assche, and W. Reinisch Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis Gastroenterology 142 2012 257 265 e1-3
122. W.J. Sandborn, B.G. Feagan, and C. Marano Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis Gastroenterology 146 2014 85 95 quiz e14-e15
123. A.C. Ford, and L. Peyrin-Biroulet Opportunistic infections with anti-tumor necrosis factor-alpha therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials Am J Gastroenterol 108 2013 1268 1276
124. L.E. Targownik, and C.N. Bernstein Infectious and malignant complications of TNF inhibitor therapy in IBD Am J Gastroenterol 108 2013 1835 1842 quiz 1843
125. C.L. Krieckaert, G.M. Bartelds, and W.F. Lems The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review Arthritis Res Ther 12 2010 217
126. M.F. Pouw, C.L. Krieckaert, and M.T. Nurmohamed Key findings towards optimising adalimumab treatment: the concentration-effect curve Ann Rheum Dis 74 2013 513 518
127. R. Panaccione, S. Ghosh, and S. Middleton Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis Gastroenterology 146 2014 392 400.e3
128. O. Adedokun, Z. Xu, and C. Marano Effects of immunomodulators on the pharmacokinetics and efficacy of golimumab in patients with moderately to severely active ulcerative colitis: Results from phase 2/3 PURSUIT-SC induction and maintenance studies (abstr) Am J Gastroenterol 108 2013 S517
129. G.R. Lichtenstein, R.H. Diamond, and C.L. Wagner Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials Aliment Pharmacol Ther 30 2009 210 226
130. J.F. Colombel, W.J. Sandborn, and W. Reinisch Infliximab, azathioprine, or combination therapy for Crohn's disease N Engl J Med 362 2010 1383 1395
131. M.T. Osterman, W.J. Sandborn, and J.F. Colombel Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease Gastroenterology 146 2014 941 949
132. W.J. Sandborn, B.G. Feagan, and C. Marano Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis Gastroenterology 146 2014 96 109 e1
133. W. Reinisch, W.J. Sandborn, and P. Rutgeerts Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies Inflamm Bowel Dis 18 2012 201 211
134. W.J. Sandborn, J.F. Colombel, and G. D'Haens One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2 Aliment Pharmacol Ther 37 2013 204 213
135. W. Reinisch, W.J. Sandborn, and R. Panaccione 52-week efficacy of adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppressants Inflamm Bowel Dis 19 2013 1700 1709
136. C.J. Williams, L. Peyrin-Biroulet, and A.C. Ford Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-alpha therapy in inflammatory bowel disease Aliment Pharmacol Ther 39 2014 447 458
137. M. Bewernitz, C. Garnett, and K. Gottlieb Assessment of adalimumab dose selection for adult ulcerative colitis using exposure-response analyses (abstr) J Pharmacokinet Pharmacodyn 40 2013 S44 S45
138. W. Reinisch, B. Feagan, and P. Rutgeerts Infliximab concentration and clinical outcome in patients with ulcerative colitis (abstr) Gastroenterology 142 2012 S-114
139. X. Roblin, H. Marotte, and M. Rinaudo Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases Clin Gastroenterol Hepatol 12 2014 80 84.e2
140. T. Hibi, A. Sakuraba, and M. Watanabe Retrieval of serum infliximab level by shortening the maintenance infusion interval is correlated with clinical efficacy in Crohn's disease Inflamm Bowel Dis 18 2012 1480 1487
141. N. Vande Casteele, A. Gils, and S. Singh Antibody response to infliximab and its impact on pharmacokinetics can be transient Am J Gastroenterol 108 2013 962 971
142. W. Afif, E.V. Loftus Jr., and W.A. Faubion Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease Am J Gastroenterol 105 2010 1133 1139
143. X. Roblin, M. Rinaudo, and E. Del Tedesco Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases Am J Gastroenterol 109 2014 1250 1256
144. S. Paul, E. Del Tedesco, and H. Marotte Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study Inflamm Bowel Dis 19 2013 2568 2576
145. B.G. Feagan, P. Rutgeerts, and B.E. Sands Vedolizumab as induction and maintenance therapy for ulcerative colitis N Engl J Med 369 2013 699 710
146. A. Parikh Efficacy of vedolizumab in ulcerative colitis by prior treatment failure in GEMINI I, a randomized, placebo-controlled, double-blind, multicenter trial (abstr P-29) Inflamm Bowel Dis 18 2012 S26
147. A. Parikh, T. Leach, and T. Wyant Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study Inflamm Bowel Dis 18 2012 1470 1479
148. A. Parikh, I. Fox, and T. Leach Long-term clinical experience with vedolizumab in patients with inflammatory bowel disease Inflamm Bowel Dis 19 2013 1691 1699
149. B. Feagan, T. Leach, and C. Milch Emerging safety profile of vedolizumab: A novel, selective integrin inhibitor for the treatment of IBD (abstr P-0025) Inflamm Bowel Dis 15 suppl 2009 S12
150. M. Rosario, T. Wyant, and C. Milch Pharmacokinetic and pharmacodynamic relationship and immunogenicity of vedolizumab in adults with inflammatory bowel disease: Additional results from the GEMINI 1 and 2 studies (abstr DOP058) J Crohns Colitis 8 2014 S42 S43
151. P. Moayyedi, J.K. Marshall, and Y. Yuan Canadian Association of Gastroenterology position statement: fecal microbiota transplant therapy Can J Gastroenterol Hepatol 28 2014 66 68
152. P. Moayyedi, M. Surette, and M. Wolfe A randomized, placebo controlled trial of fecal microbiota therapy in active ulcerative colitis (abstr 929c) Gastroenterology 146 2014 S-159
153. J. Shen, Z.X. Zuo, and A.P. Mao Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, Crohn's disease, and pouchitis: meta-analysis of randomized controlled trials Inflamm Bowel Dis 20 2014 21 35
154. H.E. Mardini, and A.Y. Grigorian Probiotic mix VSL#3 is effective adjunctive therapy for mild to moderately active ulcerative colitis: a meta-analysis Inflamm Bowel Dis 20 2014 1562 1567
155. A.M. Petersen, H. Mirsepasi, and S.I. Halkjaer Ciprofloxacin and probiotic Escherichia coli Nissle add-on treatment in active ulcerative colitis: a double-blind randomized placebo controlled clinical trial J Crohns Colitis 8 2014 1498 1505
156. S. Nikfar, S. Ehteshami-Ashar, and R. Rahimi Systematic review and meta-analysis of the efficacy and tolerability of nicotine preparations in active ulcerative colitis Clin Ther 32 2010 2304 2315
157. H. Ogata, J. Kato, and F. Hirai Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis Inflamm Bowel Dis 18 2012 803 808
158. S. Lichtiger, D.H. Present, and A. Kornbluth Cyclosporine in severe ulcerative colitis refractory to steroid therapy N Engl J Med 330 1994 1841 1845
159. G. D'Haens, L. Lemmens, and K. Geboes Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis Gastroenterology 120 2001 1323 1329
160. W. Stremmel, R. Ehehalt, and F. Autschbach Phosphatidylcholine for steroid-refractory chronic ulcerative colitis: a randomized trial Ann Intern Med 147 2007 603 610
161. M. Karner, A. Kocjan, and J. Stein First multicenter study of modified release phosphatidylcholine "LT-02" in ulcerative colitis: a randomized, placebo-controlled trial in mesalazine-refractory courses Am J Gastroenterol 109 2014 1041 1051
162. W. Stremmel, A. Braun, and A. Hanemann Delayed release phosphatidylcholine in chronic-active ulcerative colitis: a randomized, double-blinded, dose finding study J Clin Gastroenterol 44 2010 e101 e107
163. R.W. Summers, D.E. Elliott, and J.F. Urban Jr. Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial Gastroenterology 128 2005 825 832
164. W.J. Sandborn, S. Ghosh, and J. Panes Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis N Engl J Med 367 2012 616 624
165. P.D. Higgins The IBD drug pipeline-ready to deliver? Am J Gastroenterol 109 2014 1052 1054